We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00179049
First Posted: September 15, 2005
Last Update Posted: December 15, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Vanderbilt University
September 13, 2005
September 15, 2005
December 15, 2008
April 2003
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00179049 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant
Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (HSCT)
The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease.
The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease (GVHD) by determining the qualitative and quantitative changes in T regulatory cells throughout the transplant process. Their understanding of this can lead to new treatment strategies and improved clinical therapeutic implications.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions
  • Hematopoietic Stem Cell Transplantation
  • Graft vs Host Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
April 2008
Not Provided

Inclusion Criteria:

  • Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions

Exclusion Criteria:

  • Patients < 18 or > 70 years old undergoing either autologous transplant or allogeneic transplant
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00179049
BMT 030261
No
Not Provided
Not Provided
Adetola A. Kassim, MD, Vanderbilt University
Vanderbilt University
Not Provided
Principal Investigator: Adetola A Kassim, M.D. Vanderbilt University
Vanderbilt University
December 2008